Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

588 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Hancock BW, et al. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665609 Clinical Trial.
Interferon as adjuvant treatment for melanoma.
Wheatley K, Ives N, Hancock B, Gore M. Wheatley K, et al. Among authors: hancock b. Lancet. 2002 Sep 14;360(9336):878. doi: 10.1016/S0140-6736(02)09986-5. Lancet. 2002. PMID: 12243953 No abstract available.
Adjuvant interferon therapy for melanoma.
Hancock B, Wheatley K, Ives N, Gore M. Hancock B, et al. J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260. J Clin Oncol. 2005. PMID: 15800339 No abstract available.
Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study.
Cameron DA, Cornbleet MC, Mackie RM, Hunter JA, Gore M, Hancock B, Smyth JF; Scottish Melanoma Group. Cameron DA, et al. Among authors: hancock b. Br J Cancer. 2001 May 4;84(9):1146-9. doi: 10.1054/bjoc.2000.1623. Br J Cancer. 2001. PMID: 11379605 Free PMC article. Clinical Trial.
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Gore ME, et al. Among authors: hancock b. Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10. Lancet. 2010. PMID: 20153039 Free PMC article. Clinical Trial.
588 results